Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
North Shore Hospital · Royal North Shore Hospital · +22 more institutions
Abstract
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically.
Citation impact
- FWCI
- 476.20
- Percentile
- 100%
- References
- 21
Authors
24- VPVlado PerkovicCorresponding
North Shore Hospital, Royal North Shore Hospital, UNSW Sydney
- MJMeg Jardine
Concord Repatriation General Hospital, UNSW Sydney
- BNBruce Neal
The University of Sydney, Imperial College London, UNSW Sydney
- SBSéverine Bompoint
UNSW Sydney
- HJHiddo J.L. Heerspink
University of Groningen, University Medical Center Groningen
Topics & keywords
- Canagliflozin
- Medicine
- Type 2 diabetes
- Diabetes mellitus
- Diabetic nephropathy
- Nephropathy
- Dapagliflozin
- Internal medicine
- Good health and well-being